nadofaragene firadenovec-vncg

First adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer is approved by FDA

Jan 2023: The drug nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals) has been approved by the Food and Drug Administration for adult patients with high-risk, unresponsive non-muscle...
nadofaragene-firadenovec-vncg

Scan the code

Tag: nadofaragene firadenovec-vncg

Home / nadofaragene firadenovec-vncg

Categories

First adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer is approved by FDA

Information

Treatment

United States

Romania

India (Hyderabad)

Cambodia

China (Shanghai)

China (Beijing)

Hong Kong